ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "physical function"

  • Abstract Number: 0358 • ACR Convergence 2021

    Work Participation in Patients with Axial Spondyloarthritis in Germany: Results from a Multicenter, Observational Survey

    Uta Kiltz1, Kirsten Hoeper2, Ludwig Hammel3, Sebastian Lieb4, Andreas Haehle4 and Dirk Meyer-Olson5, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2Regionales Kooperatives Rheumazentrum Niedersachsen e. V.; Medizinische Hochschule Hannover, Department of Rheumatology and Immunology, Hannover, Germany,, Hannover, Germany, 3Deutsche Vereinigung Morbus Bechterew e.V.,, Schweinfurt, Germany, 4Novartis Pharma GmbH, Immunology, Hepatology and Dermatology, Nürnberg, Germany, 5m&i Fachklinik Bad Pyrmont, Hannover, Germany

    Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition often associated with impaired working participation1 not only translating to devastating outcomes for patients (pts) but…
  • Abstract Number: 0376 • ACR Convergence 2021

    Impact of Patient and Disease Characteristics on Global Functioning and Health in Patients with Axial Spondyloarthritis: A Bayesian Network Analysis of Data from an Early axSpA Cohort

    Imke Redeker1, Robert Landewé2, Désirée van der Heijde3, Sofia Ramiro4, Annelies Boonen5, Maxime Dougados6, Juergen Braun7 and Uta Kiltz7, 1German Rheumatism Research Centre (DRFZ), Berlin, Germany, 2Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, 3Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 4Leiden University Medical Center, Leiden, Netherlands, 5Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+), Maastricht, Limburg, Netherlands, 6Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, 7Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany

    Background/Purpose: Current knowledge on the health status of patients (pts.) with axial spondyloarthritis (axSpA) mainly focusses on physical function and disease activity. Using a generic…
  • Abstract Number: 1110 • ACR Convergence 2020

    Osteoarthritis-Related Knee Inflammation Measured by Ultrasound Is Associated with Performance-Based Measures of Function

    Holly Philpott1, Trevor Birmingham2, Ryan Pinto2, Dominique Arsenault2, Codie Primeau2, Edward Vasarhelyi3, Steven MacDonald3, Brent Lanting3 and Tom Appleton4, 1Western University, London, ON, Canada, 2Western University, London, Canada, 3London Health Sciences Centre, London, Canada, 4The University of Western Ontario, LONDON, ON, Canada

    Background/Purpose: Signs of inflammation in knee osteoarthritis (OA), including synovitis, are associated with worse clinical outcomes such as increased pain, risk of progression, and future…
  • Abstract Number: 1341 • ACR Convergence 2020

    Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study

    Vibeke Strand1, Philip Mease2, Enrique Soriano3, Mitsumasa Kishimoto4, Carlo Salvarani5, Nemanja Damjanov6, Jaclyn K Anderson7, Erin Blondell7, Patrick Zueger7, Christopher Saffore7 and Dafna Gladman8, 1Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 2Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 3Department of Public Health, Instituto Universitario, Escuela de Medicina Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Capital Federal, Buenos Aires, Argentina, 4Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Yokohama, Japan, 5Rheumatology Units, University of Modena and Reggio Emilia, and Azienda USL-IRCCS di Reggio Emilia, REGGIO EMILIA, Italy, 6University of Belgrade Medical School, Belgrade, Serbia, 7AbbVie Inc., North Chicago, IL, 8Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Patient-reported outcomes (PROs) are important when evaluating treatment benefits in PsA. We present an analysis of PRO data from the SELECT-PsA 1 study.Methods: SELECT-PsA…
  • Abstract Number: 1371 • ACR Convergence 2020

    Improvement in Patient-Reported Outcomes for Upadacitinib versus Placebo Among Patients with Psoriatic Arthritis and an Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs

    Vibeke Strand1, Filip Van den Bosch2, Roberto Ranza3, Ying Ying Leung4, Edit Drescher5, Apinya Lertratanakul6, Ralph Lippe7, Christopher Saffore6, Patrick Zueger6 and Peter Nash8, 1Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 2Ghent University Hospital, Ghent, Belgium, 3Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlândia, Brazil, 4Department of Rheumatology & Immunology, Singapore General Hospital, Singapore, Singapore, 5Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary, 6AbbVie Inc., North Chicago, IL, 7AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 8School of Medicine Griffith University, Brisbane, Queensland, Australia

    Background/Purpose: The efficacy and safety of upadacitinib (UPA), a selective Janus kinase inhibitor, in patients with PsA is under investigation in Phase 3 clinical trials.…
  • Abstract Number: 1459 • ACR Convergence 2020

    The Association of Frequent Knee Bending with Trajectories of Pain and Physical Function over 8 Years in Knee Osteoarthritis

    Jason Jakiela1, Dana Voinier1, Thomas Bye1, Maria Tukis1, Kiely Konyak1, Dylan Orloff1 and Daniel White1, 1University of Delaware, Newark, DE

    Background/Purpose: Frequent bending increases loading at the knee and is a risk factor for worsening knee pain associated with knee osteoarthritis (OA). Knee bending is…
  • Abstract Number: 1641 • ACR Convergence 2020

    Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab: Results from a 56-Week Randomized NSAID-Controlled Study

    David Hunter1, Tuhina Neogi2, Melvin Churchill3, Ivan Shirinsky4, Masanari Omata5, Alexander White6, Ali Guermazi2, Robert Fountaine7, Glenn Pixton8, Lars Viktrup9, Mark Brown7, Christine West10 and Kenneth Verburg11, 1Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, 2Boston University School of Medicine, Boston, MA, 3Arthritis Center of Nebraska, Lincoln, NE, 4Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia, 5Ohimachi Orthopaedic Clinic, Tokyo, Japan, 6Progessive Medical Research, Port Orange, FL, 7Pfizer Inc., Groton, CT, 8Pfizer Inc., Morrisville, NC, 9Eli Lilly and Company, Indianapolis, IN, 10Pfizer Inc, Groton, CT, 11Pfizer Inc, Groton

    Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…
  • Abstract Number: 1642 • ACR Convergence 2020

    Observed Efficacy with Subcutaneous Tanezumab Is Early and Maintained in Patients with Osteoarthritis: Results from a 56-Week Randomized NSAID-Controlled Study

    Tuhina Neogi1, David Hunter2, Melvin Churchill3, Ivan Shirinsky4, Masanari Omata5, Alexander White6, Ali Guermazi1, Robert Fountaine7, Glenn Pixton8, Lars Viktrup9, Mark Brown7, Christine West10 and Kenneth Verburg11, 1Boston University School of Medicine, Boston, MA, 2Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, 3Arthritis Center of Nebraska, Lincoln, NE, 4Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia, 5Ohimachi Orthopaedic Clinic, Tokyo, Japan, 6Progessive Medical Research, Port Orange, FL, 7Pfizer Inc., Groton, CT, 8Pfizer Inc., Morrisville, NC, 9Eli Lilly and Company, Indianapolis, IN, 10Pfizer Inc, Groton, CT, 11Pfizer Inc, Groton

    Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…
  • Abstract Number: 1645 • ACR Convergence 2020

    Placebo Group Responses in Clinical Trials of Patients with Osteoarthritis: Data from the Tanezumab Development Program

    Luana Colloca1, Robert Dworkin2, John Farrar3, Leslie Tive4, Ed Whalen5, Jerry Yang4, Lars Viktrup6, Mark Brown7, Christine West7 and Kenneth Verburg8, 1University of Maryland, Baltimore, 2University of Rochester School of Medicine and Dentistry, Rochester, NY, 3University of Pennsylvania, Philadelphia, PA, 4Pfizer Inc, New York, NY, 5Pfizer Inc, New York, 6Eli Lilly and Company, Indianapolis, IN, 7Pfizer Inc, Groton, CT, 8Pfizer Inc, Groton

    Background/Purpose: The level of placebo group response in clinical trials for chronic pain conditions is a concern for the development of novel analgesics1. Here, we…
  • Abstract Number: 1647 • ACR Convergence 2020

    An Oleuropein-based Dietary Supplement Improves Joint Function in Older People with High Knee Joint Pain

    Marie-Noelle Horcajada1, Maurice Beaumont2, Nicolas Sauvageot2, Madleen Saboundjian1, Laure Poquet1, Anne-Christine Hick3, Berenice Costes4 and Yves Henrotin5, 1Nestle Research, EPFL Innovation Park, Lausanne, Switzerland, 2Nestle Research, Clinical Development Unit, Lausanne, Switzerland, 3Artialis SA, Liège, Belgium, 4Artialis SA, Liege, Belgium, 5University of Liège, Liège, Belgium

    Background/Purpose: The aim of this study was to investigate the effects of a 6-month intervention with an Olive Leaf Extract (OLE) standardized for oleuropein content…
  • Abstract Number: 0140 • ACR Convergence 2020

    Meaningful Within-Patient Change in WOMAC Domains in Patients with Moderate-To- Severe Osteoarthritis

    Philip G Conaghan1, Robert Dworkin2, Thomas Schnitzer3, Francis Berenbaum4, Andrew Bushmakin5, Joseph Cappelleri5, Lars Viktrup6 and Lucy Abraham7, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, United Kingdom, 2University of Rochester School of Medicine and Dentistry, Rochester, NY, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 4Sorbonne Universite�, Paris, France, 5Pfizer Inc, Groton, CT, 6Eli Lilly and Company, Indianapolis, IN, 7Pfizer Inc, Tadworth, United Kingdom

    Background/Purpose: The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is a disease-specific measure of osteoarthritis (OA) symptoms (pain and stiffness) and functional impairment regularly…
  • Abstract Number: 1650 • ACR Convergence 2020

    A Double-Blind Randomized Trial to Evaluate the Efficacy of Corticosteroid Injections for Osteoarthritis of the Knee Using Mobile Devices

    Joshua Baker1, Mitesh Patel1, Tuhina Neogi2, Keith Robinson3, Alexis Ogdie1 and Carla Scanzello1, 1University of Pennsylvania, Philadelphia, PA, 2Boston University School of Medicine, Boston, MA, 3Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA

    Background/Purpose: The value of intra-articular (IA) corticosteroid injections for osteoarthritis of the knee (KOA) has recently been called into question.  Variability in clinical trial design…
  • Abstract Number: 0322 • ACR Convergence 2020

    Development and Preliminary Validation of Smartphone Sensor-based Measurement Tools for Psoriatic Arthritis

    Dan Webster1, Rebecca Haberman2, Lourdes Perez-Chada3, Stockard Simon4, Woody MacDuffie4, Michael DePhillips5, Soumya Reddy6, Alexis Ogdie7, Lara Mangravite4, Joseph Merola8 and Jose Scher2, 1Sage Bionetworks, Seattle, WA, 2NYU School of Medicine, New York City, 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4Sage Bionetworks, Seattle, 5SDP Digital, Seattle, 6NYU School of Medicine, New York, NY, 7University of Pennsylvania, Philadelphia, PA, 8Brigham and Women's Hospital, Harvard Medical School, Newton, MA

    Background/Purpose: The COVID-19 pandemic has increasingly driven clinical care into remote settings, where patients with immune-mediated and inflammatory diseases struggle to convey symptom severity to…
  • Abstract Number: 1728 • ACR Convergence 2020

    Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Study

    Martin Bergman1, Jeffrey Enejosa2, Naomi Martin2, Jessica Suboticki2, Debbie Goldschmidt3, Yan Song3 and Namita Tundia2, 1Drexel University College of Medicine, Philadelphia, PA, 2AbbVie Inc., North Chicago, IL, 3Analysis Group, Inc., Boston, MA

    Background/Purpose: In patients with active rheumatoid arthritis (RA), treatment with upadacitinib (UPA) has resulted in clinically meaningful improvements in patient-reported outcomes (PROs). This post hoc…
  • Abstract Number: 0337 • ACR Convergence 2020

    Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function

    Anna-Maria Liphardt1, Eva Manger2, Sonja Liehr2, Lisa Bieniek2, Arnd Kleyer3, David Simon3, Koray Tascilar3, Michael Sticherling4, Juergen Rech3, Georg Schett5 and Axel Hueber6, 1Friedrich-Alexander-University Erlangen-Nuremberg, Internal Medicine 3 - Rheumatology & Immunology, University Hospital Erlangen, Erlangen, Bayern, Germany, 2Departement of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Bayern, Germany, 3Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 4Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 5Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, 6Sozialstiftung Bamberg, Sektion Rheumatologie, Bamberg, Germany

    Background/Purpose: To compare the impact of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) on objective and subjective parameters of hand function.Methods: Hand function was assessed…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies